CD274 and breast carcinoma: Although breast cancer has not been known as actively immunogenic tumors, TNBC shows a higher number of tumor-infiltrating lymphocytes, which are regarded as the prognostic marker for antitumor immunotherapies [10], as well as higher PD-L1 expression [20,21] than other breast cancer types.